EWSR1-NFATC2 and FUS-NFATC2 Gene Fusion-Associated Mesenchymal Tumors: Clinicopathologic Correlation and Literature Review

Table 1

Published data of patients with tumors containing EWSR1-NFATC2 fusion.

Literature case nr	Reference	Age (y)	Gender	Site	Original diagnosis	Follow-up/outcome	Therapy
1	[22, 31]	39	M	Humerus R	ESLT	15 mo after surgery lung met	Resection post-op Chth EuroEwing 99
						26 mo after surgery bone met spine
						40 mo after surgery 2nd lung met
						48 mo after surgery ANED
2		16	M	Femur R	ESLT	ND	ND
3		21	M	Thigh R	ESLT	ND	ND
4		25	M	Femur R	ESLT	ND	ND
5	[29]	32	M	Lower limb	Myoepithelial-like “MFH”; of bone 7 y before radiation due to lymphoma	64 mo; ANED (never metastasized)	ND
6	[28]	12	M	Femur	ES	11 mo; ANED (never metastasized)	Pre-op Chth resection
7		28	M	Humerus	Lymphoma	4 y local recurrence 4 y lung metastasis “possible”	Chth (“standard protocol”)
8	[12]	42	M	Femur R		ND	ND
9	[30]	30	M	Femur L	Aggressive osteoblastoma; osteosarcoma (recurrence)	2.5 y post-op local rec 3.5 y ANED	Curettage and bone graft 2.5 y post-op Chth after local recurrence
10	[27]	24	F	Calf subcutis	Extraskeletal ES	12 mo; ANED (never recurrence or metastases)	Pre-op Chth Ewing protocol
11	[32]	ND	ND	Fibula	ESLT	ANED (how long?)	ND
12	[26]	32.7	M	Humerus	ES	ND	ND
13		12.7	F	Tibia	ES	ND	ND
14		61.5	M	Calf	ES	ND	ND
15		23.6	M	Femur	ES	ND	ND
16	Current study	34	F	Femur R	SEF	4.5 y skin metastasis 10.5 y lung metastasis 11 y ANED	Pre-op Chth EURAMOS protocol resection
17		42	M	Tibia L	Myoepithelal tumor	8.5 y ANED	Curettage resection amputation (due to surgical complications)
18		60	F	Abdomen	Myoepithelal tumor or EMC	8 mo ANED	Resection
19–24	[20]	ND	ND	ND	ES/ESLT	ND	ND
25	[23]	ND	ND	ND	ES/ESLT	ND	ND
26–32	[24]	ND	ND	ND	ES/ESLT	ND	ND

ANED: alive, no evidence of disease; Chth: chemotherapy; EMC: extraskeletal myxoid chondrosarcoma; ES: Ewing sarcoma; ESLT: Ewing sarcoma-like tumor; F: female; L: left; ND: no data; M: male; mo: months; R: right; SEF: sclerosing epithelioid fibrosarcoma; y: years.